All of our C-level executives have deep expertise in skin science and pharmaceutical innovation. In fact, they developed one of the world’s most respected dermatological skincare brands, SkinMedica. Together they created a team of smart, savvy and experienced women and partnered with the country’s most respected skin physicians.

This collaboration resulted in Colorescience - a truly skin-first line of prestige makeup that gives women the luxurious colors, textures, and finishes they expect from high-end cosmetics while delivering the science of healthy skin.

We believe beauty can be a healthy proposition. We know every woman, including ourselves, deserves cosmetics that beautify AND nourish AND protect, all at once, every single time. We are committed to creating a trustworthy beauty line that makes skin look gorgeous today, tomorrow and beyond.

Colorescience Corporate Team

Mary Fisher

Mary Fisher President & Chief Executive Officer

Mary Fisher is President, Chief Executive Officer and Board Director at Colorescience, a former division of SkinMedica Inc., where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan, Inc. for $350 million with the potential for another $25 million contingent on certain sales milestones. Ms. Fisher has more than 30 years in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She is on the board of directors of Ovascience, Zeltiq and the Neuroscience Nursing Foundation. In 2013, Ms. Fisher was honored as Ernst & Young's Entrepreneur of the Year for San Diego and also received the EY Venture Capital Award of Excellence.

Ted Ebel

Ted Ebel Chief Business Officer

Ted Ebel serves as Chief Business Officer at Colorescience. Mr. Ebel has 20 years of experience in the health, wellness and consumer products industries. Prior to Colorescience, Mr. Ebel was Senior Vice President of Corporate Development for SkinMedica, Inc. having responsibility for mergers and acquisitions, licensing, intellectual property management, market research and establishing the company's international operations. Earlier in his career, Mr. Ebel served as the Executive Director of Corporate Development at CancerVax Corporation, a biotechnology company focused on cancer immunotherapy, and as the Vice President of Strategic Ventures for MP3.com, a publicly traded internet and entertainment company. In addition, Mr. Ebel held positions in marketing and corporate development at Amgen, Inc. and began his career as a consultant in the health care practice of the management consulting firm Arthur D. Little. Mr. Ebel received his Bachelor of Science, Magna Cum Laude, from Duke University, and his MBA from the Wharton School at the University of Pennsylvania.

Steve Loomis

Steve Loomis Chief Financial Officer

Steve Loomis joined Colorescience in May 2013 as Chief Financial Officer after three years at SkinMedica, where he served as as Senior Vice President of Finance, Chief Financial Officer and Corporate Secretary. From 1996 to February 2010, Mr. Loomis served as Vice President of Finance, Chief Financial Officer and Corporate Secretary for CardioDynamics International Corporation, a publicly traded international medical device company, and in 2008, he was appointed to the additional role of Vice President of Operations. From 1993 until 1996, he served as Director of Financial Reporting at Kinko's Inc. a worldwide business service provider. From 1988 to 1993, Mr. Loomis was Chief Financial Officer for Terminal Data Corporation, a publicly traded international high technology manufacturing company. He earned his Bachelor's degree in business administration from California State University at Northridge. Mr. Loomis is a certified public accountant and has served on the board of several for-profit and not-for-profit organizations. Mr. Loomis was awarded San Diego Business Journal's 2011 CFO of the Year.


Board of Directors

Rich Aldrich

Rich Aldrich

Mr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman of the Board of Directors, Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), OvaScience (NASDAQ: OVAS), where he serves as Chairman of the Board and FlexPharma (NASDAQ FLKS). Mr. Aldrich also serves as a Director of Longwood portfolio companies Mitobridge, Inc. and Colorescience, Inc. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich also serves on the Board of the Massachusetts Eye & Ear Infirmary. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.


Josh Baltzell

Josh Baltzell

Josh Baltzell is a Managing Director with Split Rock Partners. He joined the Firm's at its inception in 2005 and provides the healthcare team with an extensive background in the medical device industry, having been involved in virtually all aspects from product development to the acquisition and sale of mature organizations.

Prior to joining Split Rock Partners, Josh served as a Principal with St. Paul Venture Capital's healthcare team, which he joined in 2002. He joined St. Paul Venture Capital from Piper Jaffray where he held the position of vice president in the healthcare investment banking group. During his tenure there, he was involved in a broad range of investment banking activities including private and public equity financings as well as mergers and acquisitions on the buy and sell side.

Prior to joining Piper Jaffray, Josh spent several years in various marketing and business development positions in the medical device industry including vice president, marketing and business development for a medical device start-up and group product manager - emerging technologies for SCIMED/Boston Scientific.

Josh graduated from St. Olaf College and has an MBA from the University of Minnesota's Carlson School of Management.


James H. Cavanaugh, Ph.D.

James H. Cavanaugh, Ph.D.

James H. Cavanaugh, Ph.D. has been a managing director of HealthCare Ventures since 1989. He was previously president of SmithKline & French Laboratories-U.S., the domestic pharmaceutical division of SmithKline Beckman Corporation. He had been president of SmithKline Beckman's clinical laboratory business and President of Allergan International. He served as staff assistant to President Nixon for Health Affairs and then deputy director of the President's Domestic Council. Under President Ford, he was a deputy assistant to the President for domestic affairs and deputy chief of the White House. He has served as deputy assistant secretary for health and scientific affairs in the United States Department of Health, Education and Welfare, special assistant to the Surgeon General, United States Public Health Services, and director, Office of Comprehensive Health Planning. He began his career as a member of the faculty of the Graduate College and the College of Medicine at the University of Iowa where he received his master's and doctorate degrees.


Brian H. Dovey

Brian H. Dovey

Brian Dovey has been a partner of Domain since 1988, where he has led innovative investments not only in life sciences companies but also in establishing and directing new initiatives, such as the collaboration with Domain and Rusnano. Since joining Domain, he has served on the board of directors of more than 35 private and public companies and has been chairman of five. He is currently on the board of two public companies, Orexigen Therapeutics and REVA Medical. Prior to Domain, Brian spent six years at Rorer Group (now part of Sanofi-Aventis). As president of Rorer from 1986 to 1988, he was the primary architect of this company's strategic shift to pharmaceuticals that resulted in a doubling of annual sales to approximately $1 billion. Previous to that, Brian was president of Survival Technology, a start-up medical products company whose sales growth placed it in the top ten of the Inc 100. He has also held management positions with Howmedica, Howmet Corporation, and New York Telephone. He received his B.A. in mathematics from Colgate University and his MBA from Harvard Business School. Currently, Brian serves on the board of directors and is chairman at the Center for Venture Education (Kauffman Fellows Program) and on the La Jolla Playhouse Board of Trustees. Brian is also on the Venture Advisory Board of the Skolkovo Foundation. He is former chair and currently serves on the Board of Trustees of the Wistar Institute, a leader in preclinical bio-medical research in the non-profit sector. Brian has served as both president and chairman of the National Venture Capital Association. He is a trustee emeritus of Germantown Academy and is a former trustee of the University of Pennsylvania School of Nursing and the Burnham Institute for Medical Research. He is also a former board member of the industry associations representing the medical device industry as well as the association representing consumer pharmaceuticals.


Mary Fisher

Mary Fisher

Mary Fisher is President, Chief Executive Officer and Board Director at Colorescience, a former division of SkinMedica Inc., where she served as Chief Executive Officer from 2008 until 2012. She led the successful sale of the company to Allergan, Inc. for $350 million with the potential for another $25 million contingent on certain sales milestones. Ms. Fisher has more than 30 years in the pharmaceutical and biotechnology industries, including management and leadership positions at Acorda Therapeutics, Cephalon, Immunex and Boehringer Ingelheim. She is on the board of directors of Ovascience, Zeltiq and the Neuroscience Nursing Foundation. In 2013, Ms. Fisher was honored as Ernst & Young's Entrepreneur of the Year for San Diego and also received the EY Venture Capital Award of Excellence.


David F. Hale

David F. Hale

David Hale is currently Chairman of Hale BioPharma Ventures, LLC, a private company involved in the development of biotechnology, specialty pharma, diagnostic and device companies. He was previously President and CEO of CancerVax Corporation, which merged with Micromet, Inc., where he served as Chairman until its acquisition by Amgen Inc. in 2012. He is a serial entrepreneur who has been involved in the formation and development of a number of biomedical companies. In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was Chairman, President and CEO of Gensia, Inc., and a co-founder and Chairman of Viagene, Inc. from 1987 to 1995. Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. Mr. Hale is Chairman of the Board of Santarus, Inc., and Conatus Pharmaceuticals Inc., which are two public biopharmaceutical companies. He also serves as Chairman of Crisi Medical Systems, Inc., Ridge Diagnostics, Inc., Agility Clinical, Inc., Advantar Laboratories, Inc., Intrepid Therapeutics, Inc., Biocept, Inc., and Katama Pharmaceuticals. He served as Chairman of SkinMedica until its acquisition by Allergan in 2012. Mr. Hale also serves on the Board of Directors of BIOCOM, the San Diego EDC and he is a co-founder and a director of CONNECT. He also serves as Chairman of the Board of Trustees of Rady Children's Hospital.


George M. Jenkins

George M. Jenkins

Mr. George M. Jenkins served as General Partner and Chief Operating Officer of Apax Partners LLP from 1987 to 2006. Apax Partners invests world wide in privately held equity investments. Currently, Mr. Jenkins isPresident of Merritt Capital Corporation. He began his career in the banking industry at Midlantic Bank, where he served as Vice President and representative for Midlantic Bank in Europe based out of London and subsequently headed its activities in Asia. Upon returning to the United States, he served as Division Head of the Special Industries and Technology group and was responsible for one of its three principal commercial lending groups, its business as an intermediary and its investment in private equity limited partnerships. Mr. Jenkins is a member of Lafayette College's Board of Trustees. He serves as the Chair of the Eagles Mere Historic Village. Mr. Jenkins holds a B.A. in Economics from Lafayette College and M.B.A. in Accounting and Finance from Pace University. He has completed advanced graduate study in Mathematics at Stevens Institute.


Nicky Kinnaird

Nicky Kinnaird

Nicky Kinnaird is a long-time, esteemed innovator in the beauty industry. She revolutionized retail beauty in the early 1990’s with the launch of Space NK Apothecary in London’s Covent Garden. The ground-breaking boutique featured a curated mix of beauty and wellbeing lines and quickly grew into an international beauty mecca—known for offering consumers a unique selection of the finest established and burgeoning brands. Having stepped down from her Space NK duties over 2 years ago, Kinnaird has fed her passion for the evolution of consumer-focused beauty by consulting on growing brands.


Daniel Turner III

Daniel Turner III

Mr. Turner has 25 years of experience as an entrepreneur, operating manager and investor. He founded Montreux and has been a General Partner and Managing Member since 1993.

Mr. Turner has invested in companies across consumer, healthcare services, pharmaceuticals and technology companies. Some of his previous investments includes Paymap (acquired by First Data Corp), Peapod (IPO; acquired by Royal Ahold), and Great Lakes Health Plan (acquired by United Healthcare). Mr. Turner is a member of the board of directors of GC Aesthetics and Moksha8. Mr. Turner previously served as Montreux's representative to the board of directors of Glaukos (NYSE: GKOS), Tobira Therapeutics, Epirus Biopharmaceuticals (NASDAQ: EPRS), Renal CarePartners (sold to Ambulatory Services of America 2011), Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005).

Mr. Turner started his career with Price Waterhouse in the high technology group. He later became the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Immediately prior to founding Montreux, Mr. Turner was a Principal in the Turnaround Group for Berkeley International.

In addition to his activities at Montreux, Mr. Turner is a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.

He holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant.